Are Cure Claims for CAR T-Cell Therapy Premature?

Submitted by blackswan on Thu, 06/08/2017 - 23:40

The top news to come out of the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), which concluded on Tuesday, focused on claims that immune cellular therapy with CAR T-cells provides a potentially curative approach for myeloma. It is way too soon, in my opinion, for such suggestions, both in terms of treatment benefit and toxicities and/or side effects.

Frontline Therapy and MRD: Exciting New Data from France

Submitted by Dr. Brian GM Durie on Thu, 07/31/2014 - 00:00

A recent study illustrates just how useful minimal residual disease (MRD) testing by flow cytometry is to predict excellent outcomes with new highly active combination therapies.